The US is buying nearly all the next three months' projected production of remdesivir from US manufacturer Gilead.
The US health department announced on Tuesday it had agreed to buy 500,000 doses for use in American hospitals.
Tests suggest remdesivir cuts recovery times, though it is not yet clear if it improves survival rates.
Gilead did sign a licensing deal in May for production outside the US but it is still in its early stages.
"President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for disease," Department of Health and Human Services Secretary Alex Azar said in a statement.
A course of treatment in the US will cost $2,340 (£1,900).
Nine companies can make the drug under licence outside the US for distribution in 127 mostly poorer countries, and the cost is lower. But the project is still in its early stages.
Additional quantities are being manufactured for use in clinical trials.
But critics say the US move to buy up so much stock from Gilead itself undermines international co-operation, given that other countries have taken part in trials of remdesivir, originally an anti-viral against Ebola.
https://www.bbc.com/news/world-us-canada-53254487
An Indo-American News website. It covers Gossips, Politics, Movies, Technolgy, and Sports News and Photo Galleries and Live Coverage of Events via Youtube. The website is established in 2015 and is owned by AGK FIRE INC.
The US is buying nearly all the next three months' projected production of remdesivir from US manufacturer Gilead. The US health department announced on Tuesday it had agreed to buy 500,000 doses for use in American hospitals. Tests suggest remdesivir cuts recovery times, though it is not yet clear if it improves survival rates. Gilead did sign a licensing deal in May for production outside the US but it is still in its early stages. "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for disease," Department of Health and Human Services Secretary Alex Azar said in a statement. A course of treatment in the US will cost $2,340 (£1,900). Nine companies can make the drug under licence outside the US for distribution in 127 mostly poorer countries, and the cost is lower. But the project is still in its early stages. Additional quantities are being manufactured for use in clinical trials. But critics say the US move to buy up so much stock from Gilead itself undermines international co-operation, given that other countries have taken part in trials of remdesivir, originally an anti-viral against Ebola. https://www.bbc.com/news/world-us-canada-53254487
This website uses cookies.